The next generation biopharmaceuticals

Interim Report – January to September 2014

2014-11-20

Interim Report – January to September 2014

Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™, today issued its Interim Report covering the Third Quarter 2014.

 

Financial Highlights

  • Revenue for the 3rd quarter 2014 SEK 11.5 (22.3) million, and for the nine month period to 33.5 (45.5) million
  • Operating result for the period amounted to SEK 0.4 (7.5) million, and for the nine month period to -3.2 (6.8) million
  • EBITDA for the period amounted to SEK 0.5 (7.6) million, and for the nine month period to -2.9 (7.0) million
  • Net result for the period amounted to SEK 0.1 (7.1) million, and for the nine month period to -4.2 (5.7) million
  • Cash flow for the period was SEK -3.4 (2.8) million, and for the nine month period to -7.1 (-0.7) million
  • Cash and cash equivalents at the end of the period amounted to SEK 26.0 (20.6) million

Significant events during the  quarter

  • No significant events were reported during the quarter

Other significant events during 2014

  • The first patient was included in a PET Imaging Study of HER2 Expression in Breast Cancer at Herlev University Hospital
  • An Annual General Meeting on May 8 elected Håkan Åström, Jakob Lindberg, Mathias Uhlén and Jonathan Knowles as Directors of the Board
  • Investor AB acquired all HealthCap’s shares in Affibody

Significant events after the end of the reporting period

  • In October 2014, Sobi decided to place the phase 1 study of SOBI002 on clinical hold as adverse events were observed in the first-in-human study. All subjects that have been dosed with SOBI002 are well. Sobi is now working to understand these adverse events.

Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.

Affibody is developing a portfolio of innovative drug projects and, in addition, offers the half-life extension technology, Albumod™, for outlicensing.

Affibody has ongoing commercial relationships with several companies including Algeta, Amylin, Sobi, GE, Daiichi-Sankyo, Daewoong and Thermo Fisher.

Affibody was founded in 1998 by researchers from the Royal Institute of Technology and the Karolinska Institute and is based in Stockholm, Sweden.

Further information can be found at: www.affibody.com

Affibody in short

Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.

Upcoming reports Financial calendar

  • Year-end report (February 24, 2017)